ArticleThe New England journal of medicine2016
Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis.
Article in The New England journal of medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Elusive B Cell Antigen in Multiple Sclerosis: Time to Rethink CNS B Cell Functions.International journal of molecular sciences · 2025Pooled it
- Absence of antibodies against KIR4.1 in multiple sclerosis: A three-technique approach and systematic review.PloS one · 2017Pooled it
- Activation of Kir4.1 Channels by 2-D08 Promotes Myelin Repair in Multiple Sclerosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Roles of Ion Channels in Oligodendrocyte Precursor Cells: From Physiology to Pathology.International journal of molecular sciences · 2025Review
- Multiple sclerosis: an immune attack on astrocyte-mediated ion and water homeostasis.Nature reviews. Neurology · 2025Review
- A Blood Test for the Diagnosis of Multiple Sclerosis.International journal of molecular sciences · 2024Article
- Antibodies from serum and CSF of multiple sclerosis patients bind to oligodendroglial and neuronal cell-lines.Brain communications · 2023Article
- Pathogenic autoantibodies in multiple sclerosis - from a simple idea to a complex concept.Nature reviews. Neurology · 2022Review
- An Update on Diagnostic Laboratory Biomarkers for Multiple Sclerosis.Current neurology and neuroscience reports · 2022Review
- Anti-Kir4.1 Antibodies in Multiple Sclerosis: Specificity and Pathogenicity.International journal of molecular sciences · 2020Review
- B cells in autoimmune and neurodegenerative central nervous system diseases.Nature reviews. Neuroscience · 2019Review
- Biomarkers in Multiple Sclerosis.Cold Spring Harbor perspectives in medicine · 2019Review
- The tension between early diagnosis and misdiagnosis of multiple sclerosis.Nature reviews. Neurology · 2017Review
- KIR4.1: KFrontiers in molecular neuroscience · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.